Evidence map›Paper›PMID 37927474›Full record

SynthesisFrontiers in oncology2023

Implant replacement and anaplastic large cell lymphoma associated with breast implants: a quantitative analysis.

Martina Vittorietti, Sergio Mazzola, Claudio Costantino, Daniele Domenico De Bella, Santo Fruscione, Nicole Bonaccorso, Martina Sciortino, Davide Costanza, Miriam Belluzzo, Alessandra Savatteri and 7 more

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Martina VittoriettiSEAS Department, University of Palermo, Palermo, Italy.
Sergio MazzolaU.O.C. of Clinical Epidemiology with Cancer Registry, Azienda Ospedaliera Universitaria Policlinico di Palermo, Palermo, Italy.
Claudio CostantinoU.O.C. of Clinical Epidemiology with Cancer Registry, Azienda Ospedaliera Universitaria Policlinico di Palermo, Palermo, Italy.
Daniele Domenico De BellaPROMISE Department, University of Palermo, Palermo, Italy.
Santo FruscionePROMISE Department, University of Palermo, Palermo, Italy.
Nicole BonaccorsoPROMISE Department, University of Palermo, Palermo, Italy.
Martina SciortinoPROMISE Department, University of Palermo, Palermo, Italy.
Davide CostanzaPROMISE Department, University of Palermo, Palermo, Italy.
Miriam BelluzzoPROMISE Department, University of Palermo, Palermo, Italy.
Alessandra SavatteriPROMISE Department, University of Palermo, Palermo, Italy.
Fabio TramutoU.O.C. of Clinical Epidemiology with Cancer Registry, Azienda Ospedaliera Universitaria Policlinico di Palermo, Palermo, Italy.
Paolo ContieroEnvironmental Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Giovanna TagliabueCancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Palmira ImmordinoPROMISE Department, University of Palermo, Palermo, Italy.
Francesco VitaleU.O.C. of Clinical Epidemiology with Cancer Registry, Azienda Ospedaliera Universitaria Policlinico di Palermo, Palermo, Italy.
Arianna Di NapoliDepartment of Clinical and Molecular Medicine, University of Rome "Sapienza", Rome, Italy.
Walter MazzuccoU.O.C. of Clinical Epidemiology with Cancer Registry, Azienda Ospedaliera Universitaria Policlinico di Palermo, Palermo, Italy.
University of Palermo · ITAzienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare form of non-Hodgkin T-cell lymphoma associated with breast reconstruction post-mastectomy or cosmetic-additive mammoplasty. The increasing use of implants for cosmetic purposes is expected to lead to an increase in BIA-ALCL cases. This study investigated the main characteristics of the disease and the factors predicting BIA-ALCL onset in patients with and without an implant replacement. Methods: A quantitative analysis was performed by two independent researchers on cases extracted from 52 primary studies (case report, case series, and systematic review) published until April 2022 and searched in PubMed, Scopus, and Google-Scholar databases using "Breast-Implant" AND/OR "Associated" AND/OR "Anaplastic-Large-Cell-Lymphoma". The statistical significance was verified by Student's Results: Overall, 232 patients with BIA-ALCL were extracted. The mean age at diagnosis was 55 years old, with a mean time to disease onset from the first implant of 10.3 years. The hazard of developing BIA-ALCL in a shorter time resulted significantly higher for patients not having an implant replacement (hazard ratio = 0.03; 95%CI: 0.005-0.19; Discussion: Our findings suggest that, in BIA-ALCL patients, the implant substitution and/or capsulectomy may delay the disease's onset. However, the risk of reoccurrence in an earlier time should be considered in these patients. Moreover, the time to BIA-ALCL onset slightly increased with age. Selection bias, lack of awareness, misdiagnosis, and limited data availability could be identified as limits of our study. An implant replacement should be considered according to a risk stratification approach to delay the BIA-ALCL occurrence in asymptomatic patients, although a stricter follow-up after the implant substitution should be recommended. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier: CRD42023446726.

Indexed as

anaplastic large cell lymphoma associated with breast implantsbreast implants replacementepidemiologyquantitative analysistime to disease onsettreatment outcomes

Identifiers

PMID37927474
PMCPMC10622658
OpenAlexW4387779454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.